Tin tức & Cập nhật
Xem bài viết Gan
Xem
Chỉ hiển thị Multimedia

FASN inhibitor for MASH with fibrosis gets a pass to phase III
28 Oct 2024
bởiJairia Dela Cruz
The oral fatty acid synthase (FASN) inhibitor denifanstat appears to produce meaningful improvements in metabolic dysfunction-associated steatohepatitis (MASH) and stage 2–3 fibrosis, as shown in the results of a phase IIb trial.
28 Oct 2024

Survodutide safe to use in cirrhosis patients
27 Oct 2024
Treatment with survodutide, which has previously shown its efficacy in reducing body weight and glycaemia in people with obesity or type 2 diabetes, is well tolerated by patients with compensated or decompensated cirrhosis, reports a study.
27 Oct 2024

New model predicts HCC risk in noncirrhotic CHB patients
07 Oct 2024
A novel prognostic model based on the viral loads of hepatitis B virus (HBV) demonstrates its utility in predicting and stratifying the risk of hepatocellular carcinoma (HCC) in noncirrhotic patients with chronic hepatitis B (CHB) who are not yet receiving antiviral therapy.
07 Oct 2024





